Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220267
Title: Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation
Author: Riera i Escalé, Antoni
Donoghue, Craig
Cubillos Rojas, Mónica
Gutierrez Prat, Núria
Sánchez Zarzalejo, Carolina
Verdaguer i Espaulella, Xavier
Nebreda, Àngel R.
Keywords: Molècules
Proteïnes quinases
Molecules
Protein kinases
Issue Date: 18-Jun-2020
Publisher: Elsevier Masson SAS
Abstract: We report the design of hetero-bifunctional small molecules that selectively target p38α and p38β for degradation. These proteolysis targeted chimeras (PROTACs) are based on an ATP competitive inhibitor of p38α and p38β, which is linked to thalidomide analogues to recruit the Cereblon E3 ubiquitin ligase complex. Compound synthesis was facilitated by the use of a copper catalyzed 'click' reaction. We show that optimization of the linker length and composition is crucial for the degradation-inducing activity of these PROTACs. We provide evidence that these chemical compounds can induce degradation of p38α and p38β but no other related kinases at nanomolar concentrations in several mammalian cell lines. Accordingly, the PROTACs inhibit stress and cytokine-induced p38α signaling. Our compounds contribute to understanding the development of PROTACs, and provide a useful tool to investigate functions of the p38 MAPK pathway and its involvement in diseases.
Note: Versió postprint del document publicat a: https://doi.org/10.1016/j.ejmech.2020.112451
It is part of: European Journal of Medicinal Chemistry, 2020, vol. 201, p. 112451
URI: https://hdl.handle.net/2445/220267
Related resource: https://doi.org/10.1016/j.ejmech.2020.112451
ISSN: 0223-5234
Appears in Collections:Articles publicats en revistes (Química Inorgànica i Orgànica)
Articles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))

Files in This Item:
File Description SizeFormat 
231456.pdf2.76 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.